aTYR PHARMA (ATYR) Current Assets (2014 - 2026)

aTYR PHARMA (ATYR) has reported Current Assets for 13 consecutive years, with $58.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Current Assets fell 33.29% year-over-year to $58.4 million; the trailing twelve-month figure through Jun 2026 stood at $58.4 million (down 33.29% YoY), and the FY2025 full-year result was $80.2 million, down 2.1% from the prior year.
• Current Assets declined to $58.4 million in Q2 2026 per ATYR's latest filing, from $67.6 million in the prior quarter.
• Across five years, Current Assets topped out at $119.4 million in Q1 2023 and bottomed at $58.4 million in Q2 2026.
• Historically, Current Assets has averaged $90.1 million across 5 years, with a median of $88.9 million in 2024.
• The sharpest annual moves came in 2022 and 2026: Current Assets surged 101.17% in 2022, then sank 33.29% in 2026.
• Over 5 years, Current Assets stood at $80.9 million in 2022, then grew by 27.35% to $103.0 million in 2023, then decreased by 20.43% to $82.0 million in 2024, then declined by 2.1% to $80.2 million in 2025, then fell by 27.26% to $58.4 million in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $58.4 million, $67.6 million, and $80.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.